Objective The International Prognostic Index (IPI) 
Introduction

Since Fisher et al (1) demonstrated in 1993 that cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), a first-generation chemotherapy regimen, was equally effective compared to three representative thirdgeneration regimens in patients with advanced aggressive non-Hodgkin's lymphoma (NHL), CHOP has been accepted widely as the best treatment for these patients. In the same year, the International Prognostic Index (IPI) was proposed by the International Non-Hodgkin's Lymphoma Prognostic Project (2) for predicting the outcome in patients with aggressive NHL; this also has had wide subsequent use. The IPI includes four distinct risk groups for which the 5-year overall survival rate (5y-OS) after treatment with chemotherapy combinations containing doxorubicin varied from 73% in the low-risk group to 26% in the high-risk group. Several randomized trials in patients in the two higher IPI risk groups have compared standard-dose combination chemotherapy against high-dose therapy (HDT) followed by autologous hematopoietic stem-cell transplantation (HDT-ASCT), including HDT-ASCT as a part of the initial therapy, up-front HDT. Several studies of up-front HDT prior to 1998 demonstrated its superiority to standard-dose therapy
. In 1999, an international consensus conference con-F i g u r e 1 . P r o t o c o l d e s i g n f o r p a t i e n t s wi t h DL B CL . ＊ 1 ；P a t i e n t s wi t h n o mo r e t h a n t wo o f t h e s e r i s k f a c t o r s :
a g e o v e r 6 0 y e a r s , s t a g e I I d i s e a s e , i n c r e a s e d s e r u m l a c t a t e d e h y d r o g e n a s e , a n d p e r f o r ma n c e s t a t u s o f 2 . ＊ 2 ；P a t i e n t s wi t h t h r e e o r mo r e o f t h e r i s k f a c t o r s . ＊ 3 ；Re p o r t e d b y T i r e l l i e t a l ( 1 8 ) .
F i g u r e 2 . Ka p l a n -Me i e r c u r v e s f o r 1 7 7 p a t i e n t s f o r o v e r a l l s u r v i v a l a c c o r d i n g t o t h e I n t e r n a t i o n a l P r o g n o s t i c I n d e x ( I P I ) ( A) a n d a g e -a d j u s t e d I P I ( B ) . L , l o w r i s k ; L I , l o w-i n t e rme d i a t e r i s k ; HI , h i g h -i n t e r me d i a t e r i s k ; H, h i g h r i s k .
T a b l e 1 . Ch a r a c t e r i s t i c s o f 1 7 7 P a t i e n t s wi t h DL B CL cerning HDT with hematopoietic stem cell transplantation in aggressive NHL recommended further comparative trials of up-front HDT in higher-risk groups (7) . Among several subsequent comparative studies, no treatment-related difference was found in three studies (8) (9) (10) 
Patients and Methods
Subjects in this study were 177 adults with DLBCL consecutively treated at our institution and four affiliated hospitals between January 1998 and May 2002. All biopsy specimens were reviewed according to the World Health Organization (WHO) classification (13
Discussion
Although Fig. 1 
